Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) generates frequent news as a clinical-stage biotechnology company advancing regenerative medicine, regenerative immunotherapy, and AI-enabled biodefense programs. News coverage on this page centers on the company’s clinical data, regulatory designations, intellectual property developments, and strategic initiatives built around its AlloStem, ImmCelz, and iPScelz platforms.
Readers can follow detailed updates on CELZ-201 (olastrocel), the company’s lead allogeneic perinatal tissue–derived cell therapy. Recent announcements include interim 180-day results from the FDA-cleared ADAPT trial in chronic lower back pain associated with degenerative disc disease, showing statistically significant and clinically meaningful improvements in functional disability and pain with a favorable safety profile. Additional news highlights FDA Fast Track designation for CELZ-201-DDT and progress in the CREATE-1 trial for new-onset Type 1 diabetes.
CELZ news also covers the company’s BioDefense Inc. subsidiary and its Burn Pit Initiative, which has received regulatory approval to proceed. Articles describe plans to build a large molecular and cellular database for veterans exposed to toxic burn pits, supported by AI-driven molecular modeling and regenerative countermeasure development using the iPScelz platform and collaborations with partners such as Greenstone Biosciences.
Investors can review press releases on patent allowances and issued patents for ImmCelz-based regenerative immunotherapy in Type 1 diabetes and heart failure, as well as corporate communications such as shareholder letters outlining platform strategy, AI integration, and clinical milestones. Capital markets updates, including warrant exercise agreements and related proxy materials, are also reflected in the news flow.
For anyone tracking CELZ, this news feed provides a centralized view of clinical trial milestones, regulatory events, biodefense initiatives, and financing disclosures that shape the company’s development as a clinical-stage biotechnology issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has announced positive one-year follow-up results for CELZ-001, a treatment for Type 2 Diabetes, showing an overall efficacy of 93% among treated patients with a significant reduction in insulin requirements. The study involved 30 participants, of whom 15 received CELZ-001, with no serious adverse effects reported. This data supports the continued development of CELZ-001 in the context of the U.S. FDA cleared CELZ-201 clinical trial. The company plans to share these results at an upcoming endocrinology conference, indicating a commitment to advancing its unique cell-based therapeutic approaches for diabetes management.
Creative Medical Technology Holdings (NASDAQ: CELZ) filed its Form 10-K for FY 2022 on March 31, 2023, detailing significant clinical and financial developments. The company reported cash reserves of $18.4 million and working capital of $15.4 million, sufficient to fund operations through March 2024. Despite unchanged gross revenue of $0.1 million, gross profit improved to $0.1 million. R&D expenses surged to $6.3 million due to various initiatives, leading to an operating loss of $10.2 million. Notably, the company advanced its clinical trials, including a Phase 1/2 trial for early Type 1 Diabetes, and gained Orphan Drug Designation for Brittle Type 1 Diabetes.